EG-007 / Evergreen Therap - LARVOL DELTA

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Head-to-Head • Metastases • Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Oct 2025 ➔ Mar 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Jul 2024 ➔ Oct 2025 | Trial primary completion date: Jul 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Mar 2024 ➔ Jul 2024 | Trial primary completion date: Mar 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Apr 2023 ➔ Dec 2025 | Trial primary completion date: Jan 2023 ➔ Dec 2025

Head-to-Head • Metastases • Trial completion date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Evergreen Therapeutics, Inc. | Trial completion date: Mar 2022 ➔ Mar 2024 | Initiation date: Dec 2021 ➔ Mar 2023 | Trial primary completion date: Feb 2022 ➔ Mar 2024

Trial completion date • Trial initiation date • Trial primary completion date • Endometrial Cancer • Oncology • Solid Tumor